<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914628</url>
  </required_header>
  <id_info>
    <org_study_id>TK008</org_study_id>
    <secondary_id>2009-012973-37</secondary_id>
    <nct_id>NCT00914628</nct_id>
  </id_info>
  <brief_title>Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia</brief_title>
  <acronym>TK008</acronym>
  <official_title>TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MolMed S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MolMed S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this randomized trial is to compare disease-free survival (DFS) in high
      risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of
      HSV-Tk donor lymphocytes or standard haploidentical HCT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delayed immune-reconstitution remains one of the main limitation of haploidentical stem cell
      transplantation. The risk of severe infections remains high for several months and CD3+
      reconstitution could take more than 10 months. The low number of lymphocytes infused with the
      graft, the degree of HLA (Human Leukocyte Antigen) disparity, and a reduced thymic function
      in adults and differences in host/donor antigen presenting cells are contributing causes.

      The infusions of HSV-TK engineered lymphocytes may represent a significant therapeutic
      improvement in haploidentical HCT (hematopoietic cell transplantation), because it remarkably
      may enhance both GvL (Graft versus Leukemia) activity, thus reducing the occurrence of
      disease relapse, and post-transplant immune reconstitution in the absence of chronic immune
      suppression, thus decreasing the rate of both post-transplant opportunistic infections and
      transplant-related mortality. Furthermore, the efficient control of GvHD achieved via the
      suicide mechanism allows also the multiple infusion of HSV-TK-treated donor lymphocytes, when
      needed, that might further improve post-transplant host immune reconstitution, and survival
      in patients receiving haplo-HCT. Finally, this therapeutic approach can become a valuable
      option for all candidates, including patients with advanced disease and older age.

      The proposed clinical trial represents an innovative therapeutic treatment for patients
      affected by high risk acute leukemia, who have undergone haploidentical stem cell
      transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2010</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>from the date of randomization, assessed up to 12 months</time_frame>
    <description>measured from the date of randomization until the date of relapse (or progression), or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from the date of randomization to the date of death, assessed up to 12 months</time_frame>
    <description>any death without previous occurrence of a documented relapse (or progression).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GvHD-free/relapse-free survival (GRFS)</measure>
    <time_frame>from the date of randomization to the date of death, assessed up to 12 months</time_frame>
    <description>the time from the date of randomization to chronic GvHD, relapse/progression or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution (IR)</measure>
    <time_frame>weekly up to IR after engraftment of HCT, monthly for 6 months from date of IR and then at month 9 and 12</time_frame>
    <description>the time to reach a level of circulating CD3+ ≥ 100/µl for two consecutive observations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate</measure>
    <time_frame>day 15 after HCT, monthly for 6 months after HCT and then at month 9 and 12</time_frame>
    <description>defined as the persistent blood cells count above predefined level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of grade 2, 3, or 4 acute GVHD (aGvHD)</measure>
    <time_frame>from the date of HCT until the date of the first occurrence of aGvHD, assessed up to 6 months</time_frame>
    <description>diagnosed and graded according to standard criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of chronic GvHD (cGvHD)</measure>
    <time_frame>from the date of HCT until the date of the first occurrence of cGvHD, assessed up to 12 months</time_frame>
    <description>diagnosed and graded according to standard NIH consensus criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of GvHD episodes</measure>
    <time_frame>From the date of start until the date of resolution and duration of immunosuppressive treatments administered for controlling GvHD assessed up to 12 months</time_frame>
    <description>Diagnosed and graded according to standard NIH consensus criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>from the date of randomization to the date of the first occurrence of relapse, assessed up to 12 months</time_frame>
    <description>Defined on the basis of morphologic evidence of leukaemia in bone marrow or other sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and duration of infectious episodes and infectious disease mortality</measure>
    <time_frame>from randomization to the date of resolution, assessed up to 12 months</time_frame>
    <description>diagnosis, monitoring and treatment of infectious relevant events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the acute and long-term toxicity related to the HSV-Tk infusions</measure>
    <time_frame>from HSV-Tk infusions to the date of resolution, assessed up to 12 months</time_frame>
    <description>Toxicity profile of HSV-Tk infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) and Medical Care Utilization (MCU) in both arms</measure>
    <time_frame>from randomization up to 12 months</time_frame>
    <description>Medical resource use data collected will be used in health economic analyses where it may be combined with other data from other sources such as cost data or other clinical parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>from the date of randomization to the date of death, assessed up to 12 months</time_frame>
    <description>Defined for all patients as any death without previous occurrence of a documented relapse (or progression)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Acute Leukemia (Category)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSV-TK engineering donor Lymphocytes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>T-cell depleted or T-cell replete strategies</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HSV-Tk</intervention_name>
    <description>Infusion of approximately 1±0.2 x 10^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>T-cell depleted or T-cell replete strategies</intervention_name>
    <description>Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Any of the following conditions:

               1. AML and ALL in 1st complete remission (CR1)

               2. AML and ALL in 2nd or subsequent CR

               3. secondary AML in CR

               4. AML and ALL in 1st or 2nd relapse or primary refractory

          -  Family donor with patient-donor number of HLA mismatches ≥ 2 (full haploidentical), or
             family donors sharing one HLA-haplotype with the patient

          -  Stable clinical conditions and life expectancy &gt; 3 months

          -  PS ECOG &lt; 2

          -  Serum creatinine &lt; 1.5 x ULN

          -  Bilirubin &lt; 1.5 x ULN; transaminases &lt; 3 x ULN

          -  Left ventricular ejection fraction &gt; 45%

          -  QTc interval &lt; 450 ms

          -  DLCO &gt; 50%

          -  Patients, or legal guardians, and donors must sign an informed consent indicating that
             they are aware this is a research study and have been told of its possible benefits
             and toxic side effects

        Exclusion Criteria:

          -  Patients with life-threatening condition or complication other than their basic
             condition

          -  Contraindication to haploidentical HCT as defined by the Investigator

          -  Patients with active CNS disease

          -  Pregnant or lactation.

        Exclusion criteria for HSV-Tk infusion:

          -  Infections requiring administration of ganciclovir or valganciclovir at the time of
             infusion

          -  GvHD requiring systemic immunosuppressive therapy

          -  Ongoing systemic immunosuppressive therapy after haploidentical HCT

          -  Administration of G-CSF after haploidentical HCT

        HSV-Tk cells can be administered after an adequate patient wash-out period (24 hours)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lambiase, MD</last_name>
    <role>Study Director</role>
    <affiliation>MolMed S.p.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabio Ciceri, MD</last_name>
    <phone>0</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayesh Mehta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jayesh Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rizwan Romee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rizwan Romee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Donato, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Donato, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Kerre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tessa Kerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Beguin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yves Beguin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Deconinck, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Olivier Bay, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Olivier Bay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Yakoub-agha, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ibrahim Yakoub-agha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Blaise, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier Blaise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Simon Rohrlich, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre-Simon Rohrlich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Mothy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mohamad Mothy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole - Institut Universitaire du Cancer de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Huynh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charitè; Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Uharek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lutz Uharek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Martin Kroger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolaus Martin Kroger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Ganser, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Eva Mischak-Weissinger, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Arnold Ganser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Mischak-Weissinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitat Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, MD</last_name>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Bunjes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Donald Bunjes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>George Papanicolaou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Yannaki, MD</last_name>
    </contact>
    <investigator>
      <last_name>Evangelia Yannaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera S.Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Mordini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Mordini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico-Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Milone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Milone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riccardo Saccardi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Riccardo Saccardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Indovina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Indovina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Presidio Molinette</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetto Bruno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benedetto Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Patriarca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Patriarca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico G. B. Rossi, Azienda ospedaliera universitaria integrata di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Benedetti, Md</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Benedetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri, MD</last_name>
      <phone>0</phone>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Narni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franco Narni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valdas Pečeliūnas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valdas Pečeliūnas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte, E.P.E.</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>João F. Lacerda, MD</last_name>
    </contact>
    <investigator>
      <last_name>João F. Lacerda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Sierra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge Serra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Parodi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rocio Parodi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Rodríguez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mercedes Rodríguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>September 12, 2018</last_update_submitted>
  <last_update_submitted_qc>September 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high risk acute leukemia</keyword>
  <keyword>HSV-TK</keyword>
  <keyword>Haploidentical HCT</keyword>
  <keyword>GvHD</keyword>
  <keyword>GvL</keyword>
  <keyword>Immunoreconstitution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No, only information requested by law will be released</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

